Editorial: Community series in new insights into innate immune cell-based immunotherapies in cancer, volume II

Adaptive T cell-centric immunotherapies, such as immune checkpoint inhibitors (ICIs) and Chimeric Antigen Receptor (CAR) T-cell therapies, have fundamentally transformed clinical oncology. However, the limitations of their therapeutic potential are becoming more evident. Many patients fail to achieve durable responses due to tumorintrinsic escape mechanisms. These challenges include low tumor mutational burden (TMB), loss of human leukocyte antigen (HLA) expression, and an aggressively immunosup